Edgewise Therapeutics (EWTX) Depreciation and Depletion (2020 - 2026)
Edgewise Therapeutics has reported Depreciation and Depletion over the past 7 years, most recently at $537000.0 for Q1 2026.
- Quarterly results put Depreciation and Depletion at $537000.0 for Q1 2026, up 4.68% from a year ago — trailing twelve months through Mar 2026 was $2.1 million (down 1.66% YoY), and the annual figure for FY2025 was $2.1 million, changed 0.0%.
- Depreciation and Depletion reached $537000.0 in Q1 2026 per EWTX's latest filing, down from $541000.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $600000.0 in Q4 2024 and bottomed at $100000.0 in Q1 2022.
- Median Depreciation and Depletion over the past 5 years was $500000.0 (2024), compared with a mean of $387882.4.
- The largest annual shift saw Depreciation and Depletion surged 302.5% in 2023 before it dropped 9.83% in 2025.
- Over 5 years, Depreciation and Depletion stood at $120000.0 in 2022, then soared by 302.5% to $483000.0 in 2023, then rose by 24.22% to $600000.0 in 2024, then fell by 9.83% to $541000.0 in 2025, then dropped by 0.74% to $537000.0 in 2026.
- Business Quant data shows Depreciation and Depletion for EWTX at $537000.0 in Q1 2026, $541000.0 in Q4 2025, and $500000.0 in Q3 2025.